抄録
This clinical study was carried out to evaluate the effectiveness of Cepharanthin®, which is one of the biscoclaurine alkaloids, in the treatment of oral mucosal lesions (oral lichen planus, aphthous stomatitis, leukoplakia, glossodynia).
Cepharanthin® has recently been applied in the treatment of many acute and chronic diseases, e. g. snakebite, leukopenia during radiation therapy or anticancer treatment, bronchial asthma, and alopecia areata.
Evaluation was conducted by an open trial after oral administration of 20 mg Cepharanthin®per day.The clinical response was graded according to the assessment of pain, degree of erosion, extent of striae, degree of ulcer, and degree of erythema.
Overall improvement and safety rate was 87.0% in orallichen planus, 83.3% in aphthous stomatitis, 80.0% in leukoplakia, and 77.8% in grossodynia.
It might be due to the fact that no side effect detected in the cases presented in this study.
